LCM
MDGL icon

Lynwood Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Lynwood Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,000
Closed -$730K – 73
2023
Q3 		$730K Buy
+5,000
New +$941K 1.92% 17

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lynwood Capital Management's MDGL Position: Q4 2023 in Review

Lynwood Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 5,000 shares — an estimated $730K sold.

Lynwood Capital Management first reported a position in MDGL in Q3 2023 and held it in 1 quarter. The position peaked at $730K in Q3 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

  • Lynwood Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 5,000 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $730K.
  • Lynwood Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Lynwood Capital Management's Madrigal Pharmaceuticals position peaked at $730K in Q3 2023.
  • 226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Lynwood Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.